Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the abl tyrosine kinase domain.
Levinson, N.M., Boxer, S.G.(2012) PLoS One 7: e29828-e29828
- PubMed: 22493660 
- DOI: 10.1371/journal.pone.0029828
- Primary Citation of Related Structures:  
3UE4 - PubMed Abstract: 
Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protein. The Abl inhibitors imatinib, nilotinib and dasatinib are currently used to treat CML, but resistance to these inhibitors is a significant clinical problem. ...